SecBot SecBot
8-K ·Filed May 5, 2026

RGEN

REPLIGEN CORP
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001193125-26-205011
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Q1 beat and raised EPS guidance reinforce confidence in the FY26 outlook. Watch for continued margin expansion from the Transformation Office and order trends in the next quarter. The Polymem divestiture removes a drag, but the $13.8M loss on sale is a one-time item. The reiterated organic revenue guidance suggests management sees sustained demand.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$125.61
T+0 close · May 5, 2026 · via day close
Latest settled
+14.32%
T+60 · $143.60
Vs SPY
+11.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $125.61entry
  2. T+1 · 7mo ago +0.12%α −1.27% · $125.76
  3. T+5 · 6mo ago −9.56%α −11.55% · $113.60
  4. T+20 · 6mo ago −3.57%α −8.52% · $121.13
  5. T+60 · 4mo ago +14.32%α +11.58% · $143.60

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Repligen reported Q1 2026 revenue of $194M (+15% YoY, +11% organic) and adjusted EPS of $0.48, beating the $0.38 consensus by 26.3%. The company reiterated FY26 organic revenue growth guidance of 9%-13% and raised adjusted EPS guidance to $1.97-$2.05. The Polymem divestiture and Transformation Office launch signal a focus on margin expansion, but the $13.8M loss on sale and ongoing restructuring charges temper the headline beat.

Key Financial Metrics

EPS
$0.48
est $0.38 · +26.3%
Revenue
$194.0M
est $192.2M · +0.9% · +15.0% YoY
Rating
strong beat
Guidance
$803M-$833M
raised
Gross Margin
55.7%

Key Facts

  • Q1 2026 revenue of $194M, up 15% YoY as reported and 11% organic
  • Adjusted EPS of $0.48 vs consensus $0.38, a 26.3% beat
  • GAAP EPS of $0.15 vs $0.10 YoY; GAAP operating margin expanded to 8.2% from 3.9%
  • Adjusted operating margin of 15.4% vs 13.8% YoY, expanding 160 bps
  • FY26 guidance reiterated: organic revenue growth 9%-13% ($803M-$833M); adjusted EPS raised to $1.97-$2.05
  • Polymem divestiture closed March 30, 2026, generating a $13.8M loss on sale
  • Transformation Office launched for site rationalization and margin optimization
  • Cash and marketable securities of $785M at quarter end, up from $768M at Dec 2025

Financial Impact

Q1 revenue beat consensus by ~$1.8M (0.9%); adjusted EPS beat by $0.10 (26.3%). FY26 adjusted EPS guidance raised by ~$0.04 at midpoint vs prior.

revenueepsoperating marginguidance

Risk Factors

  • FY26 guidance assumes 9%-13% organic growth; any macro or bioprocessing demand slowdown could pressure results
  • Transformation Office restructuring costs may weigh on near-term margins
  • Foreign exchange headwinds (~3% impact on reported revenue in Q1) could persist
  • China partnership is early-stage; execution risk in APAC expansion

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
82% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-205011
Document: 0001193125-26-205011-index.html0001193125-26-205011
Document: 0001193125-26-205011.txt0001193125-26-205011
8-K Data (Synthetic)0001193125-26-205011

US Market Status

Market Closed · Opens Wed (13h 15m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026